

# CBSA BioNews

## GlobelImmune Closes on Series B Financing

GlobelImmune successfully closed on \$34.3 million in Series B financing. This round was led by Lilly Ventures and included corporate as well as traditional venture capital funds. GlobelImmune is developing immunotherapy products called Tarmogens™ for the treatment of cancer and chronic infectious diseases.

**Baxa Corporation** was recognized as a 2005 Colorado Top Company by *Colorado Biz* magazine. The annual awards highlight the best of Colorado business – those companies demonstrating financial and operational excellence as well as a commitment to giving back to their communities.

Scientists at **Sirna Therapeutics** published a research paper in July documenting how to effectively deliver RNA drugs in non-toxic doses.

**AKTIV-DRY, LLC**, of Boulder has received a \$19.5 million grant from the Foundation for the National Institutes of Health to develop a needle-free, dry powder, inhalable measles vaccine delivered with a disposable plastic device.

**Allos Therapeutics, Inc.** published the results from its Phase 2 multi-center study of EFAPROXYN in patients with unresectable, non-small cell lung cancer receiving sequential chemoradiotherapy (S-CRT). Results from the study suggest that the addition of EFAPROXYN to S-CRT may improve survival over S-CRT alone without increasing radiation toxicity rates.

A new **Front Range Neuroscience Website** has been launched at [www.FRNG.colostate.edu](http://www.FRNG.colostate.edu).

**Accera Inc.** has received approval to provide Alzheimer's patients in its ongoing Phase 2b clinical trial the opportunity to receive Ketayns™ treatment in a formal open label six-month extension study. Ketayns™ is a first-in-class therapeutic that addresses the energy deficit observed in the brain of patients with Alzheimer's disease.

**iBalance** landed \$8.24 million in venture capital funding. The Series A financing is from Sutter Hill Ventures and Skyline Venture Partners. iBalance is developing a new procedure for knee reconstruction.

**OSI Pharmaceuticals Inc.** will purchase Eyetech for about \$935 million. OSI said the deal is part of a broader plan to diversify OSI's business into a variety of medical conditions. Eyetech focuses on ophthalmologic disease.

The **CBSA Government Relations and Public Affairs Committee** meets every first Tuesday of the month at CBSA offices.

## Join in

Call the CBSA office to volunteer for any of the following committees: Membership, Programs and Events, Technology Transfer and Sponsored Research.

## Colorado Tech Week – October 17 - 21

Technology's life-enhancing potential is infinite — and Colorado is on the cutting edge of the latest revolution. This statewide event showcases technological breakthroughs in business, academia, entertainment and sports with five days of demonstrations and events: [www.coloradotechweek.com](http://www.coloradotechweek.com).

## Exhibit at BioWest

Booths are still available. Reserve yours at [www.biowestconference.com](http://www.biowestconference.com).

## Colorado Companies Present at BIO Mid-America VentureForum

The Biotechnology Industry Organization (BIO) selected two private companies from Colorado to present at the BIO Mid-America VentureForum. MicroPhage (Longmont) and Thinc Pharmaceuticals (Aurora) joined other promising early-to late-stage companies from across the country in presenting business plans to a national audience of venture capitalists and other potential investors on September 21-23 in Minneapolis/St. Paul.

## 3rd Annual Awards Dinner – November 8th

Please join us for CBSA's 3rd Annual Awards Dinner on November 8th at the Colorado Convention Center. In addition to the 2006 award presentations, we are honored to announce the 2006 Cooley Godward Keynote Speech, featuring Dr. Thomas R. Cech, Nobel Laureate, President, Howard Hughes Medical Institute. The dinner follows the first day of BioWest.

## New President/CEO Named at National Jewish Medical and Research Center

Michael Salem, M.D., an academic researcher, surgeon, and healthcare entrepreneur, has been named the incoming President and CEO of National Jewish. Dr. Salem succeeds Lynn Taussig, M.D., who is retiring after more than 12 years in the position. Dr. Taussig and Dr. Salem will work together through the rest of the calendar year.

CONTINUED ON PAGE 8

## New Face at CBSA

CBSA would like to welcome Stephanie Kelly, our newest staff member. Stephanie joined the Association in mid-August to assist with database management and a variety of administrative functions. She recently graduated from Abraham Lincoln High School in Denver and plans to continue her education and training in law enforcement.

## Referendums C & D

CBSA supports Referendums C & D. They are essential to maintain key elements of Colorado's public infrastructure, especially higher education. Please vote on November 1st. Visit the official campaign website for information to post for your employees: [www.voteyesonc-d.com](http://www.voteyesonc-d.com).

**Myogen, Inc.** announced the pricing of an underwritten public offering of 4,675,082 shares of newly issued common stock at \$23.25 per share

before underwriting discounts and commissions. The company intends to use the net proceeds of approximately \$101 million from the financing to continue the development of its product candidates and research program.

**The following companies** were chosen to present to a panel of investors at the BioWest Conference Venture Forum on November 8th at the Colorado Convention Center: ApopLogic, AKTIV-DRY, Cytologic, Cerapedics, Thinc Pharmaceuticals, Lohocla, MBC Pharma, InViragen, Brotica and BioCare Systems. Congratulations and good luck!

The **Fitzsimons BioBusiness Incubator** is open and David Drake is the new executive director. The incubator is screening Colorado bio-science companies for potential clients. Contact David at [DDrake@colobio.com](mailto:DDrake@colobio.com). Look for more information in the December Focus.